FGFR2 and cholangiocarcinoma: Our findings should be interpreted within the rapidly evolving precision-oncology landscape of cholangiocarcinoma, in which actionable alterations—most prominently FGFR2 fusions and IDH1 variations in intrahepatic disease—already support targeted options with prospective evidence (e.g., futibatinib in FGFR2-rearranged iCCA; ivosidenib in IDH1-mutant CCA).